AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says

MT Newswires Live04-30

AbbVie (ABBV) is seen maintaining durable growth into the mid-2030s as investor concerns on competition eroding its business are "overdone," BofA Securities said in a note Thursday.

The brokerage said the growth outlook for the company's Skyrizi medication remains solid, with no evidence of slowing demand across psoriasis or inflammatory bowel disease. Johnson & Johnson's (JNJ) IL-23 products appear to be category expanding rather than taking market share from AbbVie, according to the note.

During its earnings call, AbbVie stated that Skyrizi's intellectual property extend into the mid-2030s and beyond, which the brokerage believes is a potential upside given the company's history of successfully defending drug patents.

Compared with its large-cap pharmaceutical peers, AbbVie is projected to grow revenue at about 6% per year over 5 and 7 years, versus a peer average of 3% to 4%, BofA said. At its current reasonable valuation, the company offers "one of the best" growth profiles in the industry, with room for upside on the success of its early and mid-pipeline efforts, the brokerage said.

BofA upgraded AbbVie to buy from neutral, and raised the price target to $234 from $226.

Shares of AbbVie were up more than 4% in Thursday trading.

Price: 212.77, Change: +8.88, Percent Change: +4.36

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2632465261?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 23:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632465261","market":"us","top_or_hot":-1,"title":"AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says","media":"MT Newswires Live","content":"<html><body><p> AbbVie (ABBV) is seen maintaining durable growth into the mid-2030s as investor concerns on competition eroding its business are \"overdone,\" BofA Securities said in a note Thursday.</p><p>The brokerage said the growth outlook for the company's Skyrizi medication remains solid, with no evidence of slowing demand across psoriasis or inflammatory bowel disease. Johnson &amp; Johnson's (JNJ) IL-23 products appear to be category expanding rather than taking market share from AbbVie, according to the note.</p><p>During its earnings call, AbbVie stated that Skyrizi's intellectual property extend into the mid-2030s and beyond, which the brokerage believes is a potential upside given the company's history of successfully defending drug patents.</p><p>Compared with its large-cap pharmaceutical peers, AbbVie is projected to grow revenue at about 6% per year over 5 and 7 years, versus a peer average of 3% to 4%, BofA said. At its current reasonable valuation, the company offers \"one of the best\" growth profiles in the industry, with room for upside on the success of its early and mid-pipeline efforts, the brokerage said.</p><p>BofA upgraded AbbVie to buy from neutral, and raised the price target to $234 from $226.</p><p>Shares of AbbVie were up more than 4% in Thursday trading.</p><p>Price: 212.77, Change: +8.88, Percent Change: +4.36</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-30 23:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AbbVie (ABBV) is seen maintaining durable growth into the mid-2030s as investor concerns on competition eroding its business are \"overdone,\" BofA Securities said in a note Thursday.</p><p>The brokerage said the growth outlook for the company's Skyrizi medication remains solid, with no evidence of slowing demand across psoriasis or inflammatory bowel disease. Johnson &amp; Johnson's (JNJ) IL-23 products appear to be category expanding rather than taking market share from AbbVie, according to the note.</p><p>During its earnings call, AbbVie stated that Skyrizi's intellectual property extend into the mid-2030s and beyond, which the brokerage believes is a potential upside given the company's history of successfully defending drug patents.</p><p>Compared with its large-cap pharmaceutical peers, AbbVie is projected to grow revenue at about 6% per year over 5 and 7 years, versus a peer average of 3% to 4%, BofA said. At its current reasonable valuation, the company offers \"one of the best\" growth profiles in the industry, with room for upside on the success of its early and mid-pipeline efforts, the brokerage said.</p><p>BofA upgraded AbbVie to buy from neutral, and raised the price target to $234 from $226.</p><p>Shares of AbbVie were up more than 4% in Thursday trading.</p><p>Price: 212.77, Change: +8.88, Percent Change: +4.36</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE000F7OJYX1.SGD","symbol_name":"RQI GLOBAL \"I\" (SGDHDG) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2632465261","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2632465261","pubTimestamp":1777564055,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AbbVie  is seen maintaining durable growth into the mid-2030s as investor concerns on competition eroding its business are \"overdone,\" BofA Securities said in a note Thursday.The brokerage said the growth outlook for the company's Skyrizi medication remains solid, with no evidence of slowing demand across psoriasis or inflammatory bowel disease. Johnson & Johnson's  IL-23 products appear to be category expanding rather than taking market share from AbbVie, according to the note.During its earnings call, AbbVie stated that Skyrizi's intellectual property extend into the mid-2030s and beyond, which the brokerage believes is a potential upside given the company's history of successfully defending drug patents.Compared with its large-cap pharmaceutical peers, AbbVie is projected to grow revenue at about 6% per year over 5 and 7 years, versus a peer average of 3% to 4%, BofA said. At its current reasonable valuation, the company offers \"one of the best\" growth profiles in the industry, with","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE000F7OJYX1.SGD":"RQI GLOBAL \"I\" (SGDHDG) INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","BK4007":"制药","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0426412945.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4581":"高盛持仓","POST":"Post Holdings","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","JNJ":"强生","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0861579265.USD":"联博低波幅策略股票基金A","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","ABBV":"艾伯维公司","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","BK4568":"美国抗疫概念","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC"},"translate_title":"美国银行证券表示，艾伯维预计将在2030年代中期实现持久增长","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1,"ABBV":1.5,"POST":1.5},"content_text":"AbbVie (ABBV) is seen maintaining durable growth into the mid-2030s as investor concerns on competition eroding its business are \"overdone,\" BofA Securities said in a note Thursday.The brokerage said the growth outlook for the company's Skyrizi medication remains solid, with no evidence of slowing demand across psoriasis or inflammatory bowel disease. Johnson & Johnson's (JNJ) IL-23 products appear to be category expanding rather than taking market share from AbbVie, according to the note.During its earnings call, AbbVie stated that Skyrizi's intellectual property extend into the mid-2030s and beyond, which the brokerage believes is a potential upside given the company's history of successfully defending drug patents.Compared with its large-cap pharmaceutical peers, AbbVie is projected to grow revenue at about 6% per year over 5 and 7 years, versus a peer average of 3% to 4%, BofA said. At its current reasonable valuation, the company offers \"one of the best\" growth profiles in the industry, with room for upside on the success of its early and mid-pipeline efforts, the brokerage said.BofA upgraded AbbVie to buy from neutral, and raised the price target to $234 from $226.Shares of AbbVie were up more than 4% in Thursday trading.Price: 212.77, Change: +8.88, Percent Change: +4.36","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2632465261","isCrawlerRequest":true}